Chemomab Therapeutics(US:CMMB) Globenewswireยท2025-06-30 12:00Core Insights - The SPRING trial data indicates that nebokitug is a promising first-in-class treatment for primary sclerosing cholangitis (PSC), showing substantial improvements in multiple biomarkers associated with disease progression [1][2][3] - Nebokitug has demonstrated a favorable safety profile, being well-tolerated over 48 weeks of treatment, and is advancing towards a Phase 3 registration trial [2][3][4] Company Overview - Chemomab Therapeutics is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases, with nebokitug (CM-101) being a dual activity monoclonal antibody targeting CCL24 [7] - The company has received FDA and EMA Orphan Drug designations and FDA Fast Track designation for nebokitug in the treatment of PSC, indicating its potential significance in addressing unmet medical needs [7] Clinical Trial Details - The Phase 2 SPRING trial was a double-blind, placebo-controlled study that showed nebokitug's dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects in patients with PSC [2][3] - In a prespecified subgroup of patients with moderate to advanced disease, those treated with nebokitug exhibited broad and consistent improvements in biomarkers linked to better clinical outcomes [2] Future Prospects - The company is preparing to initiate a Phase 3 trial for nebokitug, which is designed to provide a clear pathway to potential full regulatory approval [4][7] - The positive results from the SPRING trial support the advancement of nebokitug as a potential first approved therapy for PSC, a condition currently lacking effective treatments [2][4]